Projects per year
Personal profile
Education/Academic qualification
PGCert THE, University of Dundee
Doctor of Medicine, University of Cambridge
Bachelor of Arts, University of Cambridge
1 Oct 2006 → 30 Jun 2009
External positions
Medical Oncology Registrar, NHS Tayside
10 Sep 2018 → …Fingerprint Dive into the research topics where Mark Baxter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 0 Similar Profiles
eribulin
Medicine & Life Sciences
Hepatocellular Carcinoma
Medicine & Life Sciences
Trifluridine
Medicine & Life Sciences
Addison Disease
Medicine & Life Sciences
Knee Replacement Arthroplasties
Medicine & Life Sciences
Idiopathic Pulmonary Fibrosis
Medicine & Life Sciences
Seminoma
Medicine & Life Sciences
Airway Resistance
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2019 2019
- 1 Active
Establishing DNA Damage Response-Deficient (DDRD) Status in Patients with Advanced Oesophageal Adenocarcinoma who have had an Exceptional Response to First Line Chemotherapy
Baxter, M., Petty, R. & Walsh, S.
1/03/19 → 31/08/19
Project: Research
Research Output 2013 2019
Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population: Immune checkpoint inhibitor toxicity
Wei, K. Z., Baxter, M. & Casasola, R., 18 Apr 2019, In : Melanoma Management. 6, 1, 12 p., MMT13.Research output: Contribution to journal › Article
Open Access
File
Melanoma
Population
Hypophysitis
Disease-Free Survival
Demography
Metastatic seminoma with isolated gastric metastases: a case report
Mclaren, A., Baxter, M. A., Katbeh, T., Lynch, V., Fullarton, G. & White, J., 25 Jun 2019, In : Scottish Medical Journal. 5 p.Research output: Contribution to journal › Article
Open Access
File
Seminoma
Stomach
Neoplasm Metastasis
Orchiectomy
Groin
Real-world experience of trifluridine/tipiracil in patients with metastatic colorectal cancer: A multicenter United Kingdom study
Stavraka, C., Pouptsis, A., Kabuubi, P., Angelis, V., Baxter, M., Barrie, A., Costa, A., Nizam, A., De Naurois, J., Mikropoulos, C., Hill, M., Graham, J., Harris, V., Bridgewater, J. & Ross, P., 1 Feb 2019, In : Journal of Clinical Oncology. 37, 4, p. 668-668 1 p.Research output: Contribution to journal › Meeting abstract
Trifluridine
Colorectal Neoplasms
irinotecan
oxaliplatin
Thymidine Phosphorylase
Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study
Jafri, M., Kristeleit, H., Misra, V., Baxter, M., Ahmed, S., Jegnnathen, A., Jain, A., Maskell, D., Barthakur, U., Edwards, G., Walter, H., Walter, R., Khan, M. A., Borley, A., Nightingale, P. & Rea, D., Oct 2018, In : Annals of Oncology. 29, Supplement 8, 1 p., 313P.Research output: Contribution to journal › Conference article
eribulin
Breast Neoplasms
Survival
1
Citation
(Scopus)
39
Downloads
(Pure)
Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma
Baxter, M. A., Glen, H. & Evans, T. R. J., Aug 2018, In : Future Oncology. 14, 20, p. 2021-2029 9 p.Research output: Contribution to journal › Article
Open Access
File
Hepatocellular Carcinoma
Therapeutics
Protein-Tyrosine Kinases
Survival
lenvatinib